First-in-class humanized FSH blocking antibody targets bone and fat.
Proc Natl Acad Sci U S A. 2020 Oct 30;: Authors: Gera S, Sant D, Haider S, Korkmaz F, Kuo TC, Mathew M, Perez-Pena H, Xie H, Chen H, Batista R, Ma K, Cheng Z, Hadelia E, Robinson C, Macdonald A, Miyashita S, Williams A, Jebian G, Miyashita H, Gumerova A, Ievleva K, Smith P, He J, Ryu V, DeMambro V, Quinn MA, Meseck M, Kim SM, Kumar TR, Iqbal J, New MI, Lizneva D, Rosen CJ, Hsueh AJ, Yuen T, Zaidi M
Blocking the action of FSH genetically or pharmacologically in mice reduces body fat, lowers serum cholesterol, and increases bone mass, making an anti-FSH agent a potential therapeutic for three global epidemics: obesity, osteoporosis, and hypercholesterolemia. Here, we report the generation, structure, and function of a first-in-class, fully humanized, epitope-specific FSH blocking antibody with a K D of 7 nM. Protein thermal shift, molecular dynamics, and fine mapping of the FSH-FSH receptor interface confirm stable binding of the Fab domain to two of five receptor-interacting residues of the FSHβ subunit, which is sufficient to block its interaction with the FSH receptor. In doing so, the humanized antibody profoundly inhibited FSH action in cell-based assays, a prelude to further preclinical and clinical testing. PMID: 33127753 [PubMed - as supplied by publisher]